We provide you with 20 years of free, institutional-grade data for VYGR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of VYGR. Explore the full financial landscape of VYGR stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2024-02-28 | 1640266 | VYGR | 10-K | Url |
| 2023-11-06 | 1640266 | VYGR | 10-Q | Url |
| 2023-08-03 | 1640266 | VYGR | 10-Q | Url |
| 2023-05-09 | 1640266 | VYGR | 10-Q | Url |
| 2023-03-07 | 1640266 | VYGR | 10-K | Url |
| 2022-11-08 | 1640266 | VYGR | 10-Q | Url |
| 2022-08-04 | 1640266 | VYGR | 10-Q | Url |
| 2022-05-04 | 1640266 | VYGR | 10-Q | Url |
| 2022-03-08 | 1640266 | VYGR | 10-K | Url |
| 2021-11-02 | 1640266 | VYGR | 10-Q | Url |
| 2021-08-09 | 1640266 | VYGR | 10-Q | Url |
| 2021-05-10 | 1640266 | VYGR | 10-Q | Url |
| 2021-02-25 | 1640266 | VYGR | 10-K | Url |
| 2020-11-09 | 1640266 | VYGR | 10-Q | Url |
| 2020-08-10 | 1640266 | VYGR | 10-Q | Url |
| 2020-05-06 | 1640266 | VYGR | 10-Q | Url |
| 2020-03-03 | 1640266 | VYGR | 10-K | Url |
| 2019-11-06 | 1640266 | VYGR | 10-Q | Url |
| 2019-08-09 | 1640266 | VYGR | 10-Q | Url |
| 2019-05-07 | 1640266 | VYGR | 10-Q | Url |
| 2019-02-26 | 1640266 | VYGR | 10-K | Url |
| 2018-11-07 | 1640266 | VYGR | 10-Q | Url |
| 2018-08-07 | 1640266 | VYGR | 10-Q | Url |
| 2018-05-10 | 1640266 | VYGR | 10-Q | Url |
| 2018-03-14 | 1640266 | VYGR | 10-K | Url |
| 2017-11-02 | 1640266 | VYGR | 10-Q | Url |
| 2017-08-08 | 1640266 | VYGR | 10-Q | Url |
| 2017-05-09 | 1640266 | VYGR | 10-Q | Url |
| 2017-03-15 | 1640266 | VYGR | 10-K | Url |
| 2016-11-10 | 1640266 | VYGR | 10-Q | Url |
| 2016-08-11 | 1640266 | VYGR | 10-Q | Url |
| 2016-05-12 | 1640266 | VYGR | 10-Q | Url |
| 2016-03-17 | 1640266 | VYGR | 10-K | Url |
| 2015-12-17 | 1640266 | VYGR | 10-Q | Url |
| 2015-10-09 | 1640266 | VYGR | S-1 | Url |
Voyager Therapeutics, Inc(NASDAQ:VYGR) 
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's ...
Website: http://www.voyagertherapeutics.com
Founded: 2013
Full Time Employees: 185
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about VYGR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.